Targeted Genetics CEO Receives Entrepreneurial Achievement Award

Apr 18, 2001, 01:00 ET from Targeted Genetics Corporation

    SEATTLE, April 18 /PRNewswire/ --
 Targeted Genetics Corporation (Nasdaq:   TGEN) today announced that H. Stewart
 Parker, the Company's President and Chief Executive Officer, has received the
 Annual Entrepreneurial Achievement Award from the Forum for Women
 Entrepreneurs (FWE). The award will be presented to Ms. Parker next month.
     The award is presented to the Northwest Area woman who exemplifies FWE's
 spirit of entrepreneurship, not only for making significant and critical
 contributions to an emerging high-technology or life science company's
 development, but also for offering time and wisdom to her community and other
 entrepreneurs.
     "I am honored to be chosen as the recipient of this award," said
 Ms. Parker. "I support the Forum's efforts to highlight the opportunities that
 exist for women in the growing life science and technology industries.
 Although this award is being presented to me, I accept it on behalf of all the
 employees at Targeted Genetics, men and women, who are innovators in the
 exciting area of gene delivery technologies. I believe that the success we
 have achieved as a company is a direct result of encouraging diversity and
 seeking excellence in our employees, who come from all walks of life."
     Founded in 1993, the Forum for Women Entrepreneurs is the premier
 entrepreneurial organization for women founding and building high-growth
 technology and life science companies. Its mission is to accelerate women's
 opportunities to start, build, manage and invest in market-leading companies.
 FWE offers innovative programs, access to top-tier funding sources and a
 collaborative online community that accelerates women entrepreneurs' ability
 to launch and build world-class companies. FWE has over 1,300 members and
 offices in the Bay Area, Seattle, Colorado, Southern California and Texas.
     "Stewart Parker has overcome a number of challenges to build a company on
 the cutting edge of life sciences research and development," said
 Sharelle Klaus, president of FWE, Seattle Office. "Ms. Parker has earned
 national recognition as a leader in the biotechnology industry and the field
 of genetic therapies. In addition to her business and entrepreneurial skills,
 she is consistently respectful of the dignity and humanity of those who will
 benefit from the industry's products. Her courage and vision recently helped
 make possible a groundbreaking alliance with a nonprofit foundation to develop
 an AIDS vaccine that may have particular utility in developing nations."
     Targeted Genetics Corporation develops gene therapy products for the
 treatment of acquired and inherited diseases. The Company has lead clinical
 product development programs targeting cystic fibrosis and cancer, and a
 promising pipeline of product candidates focused on hemophilia A, arthritis,
 cancer, cardiovascular disease and AIDS prophylaxis. The Company has a broad
 platform of gene delivery technologies and, through its majority-owned
 subsidiary, CellExSys, a promising body of technology for cellular therapy.
 For more information about Targeted Genetics Corporation please visit the
 Company's web site at http://www.targetedgenetics.com .
     NOTE:  This release contains forward-looking statements relating to the
 Company's products under development, technologies and future operating
 results. These forward-looking statements are subject to certain risks and
 uncertainties that are difficult to predict and that could cause actual
 results to differ materially from those projected. Words such as "believes,"
 "expects," "intends," "anticipates," and similar expressions identify
 forward-looking statements, but their absence does not mean that the statement
 is not forward-looking. These statements are not guarantees of future
 performance. Factors that could affect the Company's actual results include
 the need for additional capital, the early stage of product development,
 uncertainties related to clinical trials, and uncertainties related to patent
 position. You should refer to the Company's Annual Report on Form 10-K for the
 year ended December 31, 2000 filed with the SEC for a more detailed
 description of these and other factors. Readers are cautioned not to place an
 undue reliance on these forward-looking statements, which speak only as of the
 date of this release. The Company undertakes no obligation to update publicly
 any forward-looking statements to reflect new information, events or
 circumstances after the date of this release or to reflect the occurrence of
 unanticipated events.
 
 

SOURCE Targeted Genetics Corporation
    SEATTLE, April 18 /PRNewswire/ --
 Targeted Genetics Corporation (Nasdaq:   TGEN) today announced that H. Stewart
 Parker, the Company's President and Chief Executive Officer, has received the
 Annual Entrepreneurial Achievement Award from the Forum for Women
 Entrepreneurs (FWE). The award will be presented to Ms. Parker next month.
     The award is presented to the Northwest Area woman who exemplifies FWE's
 spirit of entrepreneurship, not only for making significant and critical
 contributions to an emerging high-technology or life science company's
 development, but also for offering time and wisdom to her community and other
 entrepreneurs.
     "I am honored to be chosen as the recipient of this award," said
 Ms. Parker. "I support the Forum's efforts to highlight the opportunities that
 exist for women in the growing life science and technology industries.
 Although this award is being presented to me, I accept it on behalf of all the
 employees at Targeted Genetics, men and women, who are innovators in the
 exciting area of gene delivery technologies. I believe that the success we
 have achieved as a company is a direct result of encouraging diversity and
 seeking excellence in our employees, who come from all walks of life."
     Founded in 1993, the Forum for Women Entrepreneurs is the premier
 entrepreneurial organization for women founding and building high-growth
 technology and life science companies. Its mission is to accelerate women's
 opportunities to start, build, manage and invest in market-leading companies.
 FWE offers innovative programs, access to top-tier funding sources and a
 collaborative online community that accelerates women entrepreneurs' ability
 to launch and build world-class companies. FWE has over 1,300 members and
 offices in the Bay Area, Seattle, Colorado, Southern California and Texas.
     "Stewart Parker has overcome a number of challenges to build a company on
 the cutting edge of life sciences research and development," said
 Sharelle Klaus, president of FWE, Seattle Office. "Ms. Parker has earned
 national recognition as a leader in the biotechnology industry and the field
 of genetic therapies. In addition to her business and entrepreneurial skills,
 she is consistently respectful of the dignity and humanity of those who will
 benefit from the industry's products. Her courage and vision recently helped
 make possible a groundbreaking alliance with a nonprofit foundation to develop
 an AIDS vaccine that may have particular utility in developing nations."
     Targeted Genetics Corporation develops gene therapy products for the
 treatment of acquired and inherited diseases. The Company has lead clinical
 product development programs targeting cystic fibrosis and cancer, and a
 promising pipeline of product candidates focused on hemophilia A, arthritis,
 cancer, cardiovascular disease and AIDS prophylaxis. The Company has a broad
 platform of gene delivery technologies and, through its majority-owned
 subsidiary, CellExSys, a promising body of technology for cellular therapy.
 For more information about Targeted Genetics Corporation please visit the
 Company's web site at http://www.targetedgenetics.com .
     NOTE:  This release contains forward-looking statements relating to the
 Company's products under development, technologies and future operating
 results. These forward-looking statements are subject to certain risks and
 uncertainties that are difficult to predict and that could cause actual
 results to differ materially from those projected. Words such as "believes,"
 "expects," "intends," "anticipates," and similar expressions identify
 forward-looking statements, but their absence does not mean that the statement
 is not forward-looking. These statements are not guarantees of future
 performance. Factors that could affect the Company's actual results include
 the need for additional capital, the early stage of product development,
 uncertainties related to clinical trials, and uncertainties related to patent
 position. You should refer to the Company's Annual Report on Form 10-K for the
 year ended December 31, 2000 filed with the SEC for a more detailed
 description of these and other factors. Readers are cautioned not to place an
 undue reliance on these forward-looking statements, which speak only as of the
 date of this release. The Company undertakes no obligation to update publicly
 any forward-looking statements to reflect new information, events or
 circumstances after the date of this release or to reflect the occurrence of
 unanticipated events.
 
 SOURCE  Targeted Genetics Corporation

RELATED LINKS

http://www.targen.com